These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12147624)

  • 21. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
    Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
    J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
    Hong C; Lee H; Oh M; Kang CY; Hong S; Park SH
    J Immunol; 2006 Nov; 177(10):6747-57. PubMed ID: 17082588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.
    Smyth MJ; Taniguchi M; Street SE
    J Immunol; 2000 Sep; 165(5):2665-70. PubMed ID: 10946296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perforin- and Fas-dependent mechanisms of natural killer cell-mediated rejection of incompatible bone marrow cell grafts.
    Taylor MA; Ward B; Schatzle JD; Bennett M
    Eur J Immunol; 2002 Mar; 32(3):793-9. PubMed ID: 11870623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions.
    Seo N; Tokura Y; Furukawa F; Takigawa M
    J Immunol; 1998 Oct; 161(8):4138-45. PubMed ID: 9780186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
    Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
    J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
    Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
    Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
    Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
    Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
    Kline J; Zhang L; Battaglia L; Cohen KS; Gajewski TF
    J Immunol; 2012 Mar; 188(6):2630-42. PubMed ID: 22312128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
    Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
    Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells.
    Hiltbold EM; Ciborowski P; Finn OJ
    Cancer Res; 1998 Nov; 58(22):5066-70. PubMed ID: 9823312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
    Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
    Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.